Topic:

M&A

Latest Headlines

Latest Headlines

Will threats of an inversion crackdown quash pharma's foreign-deal bonanza?

U.S. legislators are threatening to make it more difficult for American companies to take off for a new home in a tax-advantaged country. But what's in store for drugmakers who have already wrapped their own so-called tax inversion deals--and those who are planning them for the future?

Med tech M&A gets much, much bigger during the first half

Not only are we going to walk you through the top med tech M&A deals of the first half of 2014, but we will take a look back to how the acquisitions from the first half of 2013 are working out and if the acquirer got exactly what they bargained for.

Deal-minded Venn buys another CRO

CRO Venn Life Sciences is spreading its reach around Europe through M&A, buying up a French outsourcer to bolster its abilities in data management.

Boston Scientific down on disclosure of subpoena about Bridgepoint acquisition

A Securities and Exchange Commission filing from Aug. 6 disclosed that Boston Scientific received a subpoena from the U.S. Attorney for the District of New Jersey regarding its acquisition of Bridgepoint Medical, leading to a sharp decline in trading. 

Pharma shares sink as U.S. threatens tax-inversion crackdown

U.S. drugmakers have embraced the tax inversion strategy with open arms as of late, buying up foreign companies right and left and hauling overseas to take advantage of their lower rates. But U.S. officials are looking to stop them in their tracks--an intent that has some pharma investors worried.

St. Jude seals the deal with NeuroTherm to gain ground in neuromodulation

St. Jude Medical finalized its acquisition of interventional pain management therapy manufacturer NeuroTherm, gaining ground in a highly competitive neuromodulation market and expanding its chronic pain portfolio.

Pfizer needs to ink a big deal, pronto. GSK or Actavis, maybe?

A couple of things happened this past week to set off new chatter about a Pfizer megadeal. First, GlaxoSmithKline posted disappointing earnings and cut its full-year forecast, sending its stock into the dumpster--and its market cap tumbling. Then, Berenberg analysts issued an investor note extolling the potential virtues of a Pfizer-GlaxoSmithKline combo. Let the speculation continue.

In a surprise twist, Treasury takes aim at Big Pharma's tax inversion deals

Tax inversions are one of the hottest trends in biopharma. But with lawmakers unable so far to reach a deal on new legislation, the Obama administration is signaling that it wants to put a stop to it--now. And it's looking for a way to go it alone, leaving lawmakers on the sidelines.

UCB hops on pharma's spinoff wagon with potential $2B sale of generics business

Shedding noncore assets is the trend du jour in Big Pharma, and now another company may be jumping on the bandwagon. Belgium's UCB is reportedly looking into a sale of Kremers Urban Pharmaceuticals, its Princeton, NJ-based generics unit.

Ackman's crusade for Valeant-Allergan combo gets a key nod from proxy advisers

Bill Ackman hasn't rounded up enough support to call the special meeting of Allergan shareholders that's crucial to Valeant's buyout bid. But now, he's got a proxy advisory firm to back his cause.